Orally administered Polypodium leucotomos extract decreases psoralen-UVA-induced phototoxicity, pigmentation, and damage of human skin

Journal of the American Academy of Dermatology

Volumn 50, Issue 1, 2004, Pages 41-49

  Middelkamp Hup, Maritza A ^a   Pathak, Madhu A ^a   Parrado, Concepcion ^a,b   Garcia Caballero, Tomas ^c   Rius Díaz, Francisca ^a,b   Fitzpatrick, Thomas B ^a   González, Salvador ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSIDAD DE MÁLAGA   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

METHOXSALEN; PLANT EXTRACT; POLYPODIUM LEUCOTOMOS EXTRACT;

ACUTE TOXICITY; ADULT; ARTICLE; FEMALE; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LANGERHANS CELL; MALE; MAST CELL; MICROVASCULATURE; NORMAL HUMAN; PHOTOTOXICITY; POLYPODIACEAE; PRIORITY JOURNAL; PUNCH BIOPSY; PUVA; RADIATION EXPOSURE; SKIN BIOPSY; SKIN CARCINOGENESIS; SKIN PIGMENTATION; SKIN PROTECTION; SKIN TOXICITY; ULTRAVIOLET A RADIATION;

POLYPODIUM LEUCOTOMOS;

EID: 0346373792     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(03)02732-4     Document Type: Article

References (61)

1. Parrish JA, Fitzpatrick TB, Tanenbaum L, Pathak MA. Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med 1974;291:1207-11.
2. Wolff K, Hönigsmann H, Gschnait F, Konrad K. Photochemo-therapie bei psoriasis: klinische erfahrungen bei 152 patienten. Dtsch Med Wochenschr 1975;100:2471-7.
3. Melski JW, Tanenbaum L, Parrish JA, Fitzpatrick TB, Bleich HL. Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. J Invest Dermatol 1977;68: 328-35.
4. Honig B, Morison WL, Karp D. Photochemotherapy beyond psoriasis. J Am Acad Dermatol 1994;31:775-90.
5. Tanew A, Radakovic-Fijan S, Schemper M, Hönigsmann H. Narrowband UV-B phototherapy vs photochemotherapy in the treatment of chronic plaque-type psoriasis: a paired comparison study. Arch Dermatol 1999;135:519-24.
6. Gilchrest BA, Parrish JA, Tanenbaum L, Haynes HA, Fitzpatrick TB. Oral methoxsalen photochemotherapy of mycosis fungoides. Cancer 1976;38:683-9.
7. Johnson R, Staiano-Coico L, Austin L, Cardinale I, Nabeya-Tsukifuji R, Krueger JG. PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in human T-lymphocytes. Photochem Photobiol 1996;63:566-71.
8. Hónigsmann H, Szeimies RM, Knobler R, Fitzpatrick TB, Pathak MA, Wolff K. Photochemotherapy and photodynamic therapy. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, et al, editors. Fitzpatrick's dermatology in general medicine. 5th ed. New York: McGraw-Hill, 1999. p. 2880-900.
9. Cech T, Pathak MA, Biswas RK. An electron microscopic study of the photochemical cross-linking of DNA in guinea pig epidermis by psoralen derivatives. Biochim Biophys Acta 1979;562:342-60.
10. -) by psoralens and ultraviolet radiation (320-400 nm). Biochim Biophys Acta 1984;798:115-26.
11. Carraro C, Pathak MA. Studies on the nature of in vitro and in vivo photosensitization reactions by psoralens and porphyrins. J Invest Dermatol 1988;90:267-75.
12. Bech-Thomsen N, Wulf HC. Photoprotection due to pigmentation and epidermal thickness after repeated exposure to ultraviolet light and psoralen plus ultraviolet A therapy. Photodermatol Photoimmunol Photomed 1996;11:213-8.
13. Friedmann PS. Disappearance of epidermal Langerhans cells during PUVA therapy. Br J Dermatol 1981;105:219-21.
14. Stern RS, Lunder EJ. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA): a meta-analysis. Arch Dermatol 1998;134:1582-5.
15. Hannuksela-Svahn A, Pukkala E, Laara E, Poikolainen K, Karvonen J. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 2000;114:587-90.
16. McKenna KE, Patterson CC, Handley J, McGinn S, Allen G. Cutaneous neoplasia following PUVA therapy for psoriasis. Br J Dermatol 1996;134:639-42.
17. Maier H, Schemper M, Ortel B, Binder M, Tanew A, Hönigsmann H. Skin tumors in photochemotherapy for psoriasis: a single-center follow-up of 496 patients. Dermatology 1996;193:185-91.
18. Lindelof B, Sigurgeirsson B, Tegner E, Larko O, Johannesson A, Berne B, et al. PUVA and cancer risk: the Swedish follow-up study. BrJ Dermatol 1999;141:108-12.
19. Horvath A, Alvarado F, Szocs J, de Alvardo ZN, Padilla G. Metabolic effects of calagualine, an antitumoral saponine of Polypodium leucotomos. Nature 1967;214:1256-8.
20. Gonzalez S, Pathak MA. Inhibition of ultraviolet-induced formation of reactive oxygen species, lipid peroxidation, erythema and skin photosensitization by Polypodium leucotomos. Photodermatol Photoimmunol Photomed 1996;12:45-56.
21. Gomes AJ, Lunardi CN, Gonzalez S, Tedesco AC. The antioxidant action of Polypodium leucotomos extract and kojic acid: reactions with reactive oxygen species. Braz J Med Biol Res 2001;34: 1487-94.
22. Gonzalez S, Pathak MA, Cuevas J, Villarrubia VG, Fitzpatrick TB. Topical or oral administration with an extract of Polypodium leucotomos prevents acute sunburn and psoralen-induced phototoxic reactions as well as depletion of Langerhans cells in human skin. Photodermatol Photoimmunol Photomed 1997;13:50-60.
23. Krenacs L, Tiszalvics L, Krenacs T, Bournsell L. Immunohistochemical detection of CD1A antigen in formalin-fixed and paraffin-embedded tissue sections with monoclonal antibody 010. J Pathol 1993;171:99-104.
24. Key G, Becker MH, Baron B, Duchrow M, Schluter C, Flad HD, et al. New Ki-67-equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest 1993;68:629-36.
25. Irani AM, Bradford TR, Kepley CL, Schechter NM, Schwartz LB. Detection of MCT and MCTC types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibodies. J Histochem Cytochem 1989;37:1509-15.
26. Miettinen M, Lindenmayer AE, Chaubal A. Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigens-evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor. Mod Pathol 1994;7:82-90.
27. Kane KS, Maytin EV. Ultraviolet B-induced apoptosis of keratinocytes in murine skin is reduced by mild local hyperthermia. J Invest Dermatol 1995;104:62-7.
28. Massi D, Franchi A, Borgognoni L, Paglierani M, Reali M, Santucci M. Tumor angiogenesis as a prognostic factor in thick cutaneos malignant melanoma: a quantitative morphologic analysis. Virchows Arch 2002;440:22-8.
29. Housman TS, Rohrback JM, Fleischer AB Jr, Feldman SR. Phototherapy utilization for psoriasis is declining in the United States. J Am Acad Dermatol 2002;46:557-9.
30. Slaper H, Schothorst AA, van der Leun JC. Risk evaluation of UVB therapy for psoriasis: comparison of calculated risk for UVB therapy and observed risk in PUVA-treated patients. Photodermatol 1986;3:271-83.
31. Young AR. Carcinogenecity of UVB phototherapy assessed. Lancet 1995;345:1431-2.
32. Pabsch H, Rutten A, Von Stemm A, Meigel W, Sander CA, Schaller J. Treatment of childhood mycosis fungoides with topical PUVA. J Am Acad Dermatol 2002;47:557-61.
33. Gordon PM, Diffey BL, Matthews JN, Farr PM. A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J Am Acad Dermatol 1999;41: 728-32.
34. Boer J, Hermans J, Schothorst AA, Suurmond D. Comparison of phototherapy (UV-B) and photochemotherapy (PUVA) for clearing and maintenance therapy of psoriasis. Arch Dermatol 1984; 120:52-7.
35. Spuls PI, Bossuyt PM, van Everdingen JJ, Witkamp L, Bos JD. The development of practice guidelines for the treatment of severe plaque form psoriasis. Arch Dermatol 1998;134:1591-6.
36. Hobbs J, Lebwohl M, Lim HW. Improving the safety profile of long-term PUVA therapy. J Am Acad Dermatol 1999;41:408-13.
37. Padilla HC, Lainez H, Pacheco JA. A new agent (hydrophilic fraction of Polypodium leucotomos) for management of psoriasis. Int J Dermatol 1974;13:276-82.
38. Jimenez D, Naranjo R, Doblare E, Munoz C, Vargas JF. Anapsos, an anti-psoriatic drug, in atopic dermatitis. Allergol Immunopathol (Madr) 1987;15:185-9.
39. Mohammad A. Vitiligo repigmentation with Anapsos (Polypodium leucotomos). Int J Dermatol 1989;28:479.
40. Spanish Ministery of Health. Polypodium leucotomos extract (Difur) in the treatment of psoriasis and atopic dermatitis. Assigned registration No. 55,757. January 5, 1982.
41. Godar DE. Light and death: photons and apoptosis. J Invest Dermatol Symp Proc 1999;4:17-23.
42. Koulu L, Jansen CT. Effect of oral methoxsalen photochemotherapy on human Langerhans cell number: dose-response and time-sequence studies. Arch Dermatol Res 1982;274:79-83.
43. Horio T, Okamoto H. Oxygen intermediates are involved in ultraviolet radiation-induced damage of Langerhans cells. J Invest Dermatol 1987;88:699-702.
44. Yuen KS, Halliday GM. Alpha-tocopherol, an inhibitor of epidermal lipid peroxidation, prevents ultraviolet radiation from suppressing the skin immune system. Photochem Photobiol 1997; 65:587-92.
45. Baba T, Nakano H, Tamai K, Sawamura D, Hanada K, Hashimoto I, et al. Inhibitory effect of beta-thujaplicin on ultraviolet B-induced apoptosis in mouse keratinocytes. J Invest Dermatol 1998;110:24-8.
46. Punnonen K, Jansen CT, Puntala A, Ahotupa M. Effects of in vitro UVA irradiation and PUVA treatment on membrane fatty acids and activities of antioxidant enzymes in human keratinocytes. J Invest Dermatol 1991;96:255-9.
47. Ikai K, Danno K, Horio T, Narumiya S. Effect of ultraviolet irradiation on mast cell-deficient W/Wv mice. J Invest Dermatol 1985; 85:82-4.
48. Kumar JR, Haberman HF, Ranadive NS. Comparative studies on the tolerance to photoinduced cutaneous inflammatory reactions by psoralen and rose bengal. J Photochem Photobiol B 1997;37:245-53.
49. Hannuksela-Svahn A, Paakko P, Autio P, Reunala T, Karvonen J, Vahakangas K. Expression of p53 protein before and after PUVA treatment in psoriasis. Acta Derm Venereol 1999;79:195-9.
50. Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001;44:755-61.
51. Hannuksela-Svahn A, Sigurgeirsson B, Pukkala E, Lindelof B, Berne B, Hannuksela M, et al. Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis. BrJ Dermatol 1999;141:497-501.
52. Imlay JA, Linn S. DNA damage and oxygen radical toxicity. Science 1988;240:1302-9.
53. Cerutti PA. Prooxidant states and tumor promotion. Science 1985;227:375-81.
54. Cavanagh LL, Sluyter R, Henderson KG, Barnetson RS, Halliday GM. Epidermal Langerhans' cell induction of immunity against an ultraviolet-induced skin tumour. Immunology 1996;87:475-80.
55. Grabbe S, Bruvers S, Gallo RL, Knisely TL, Nazareno R, Granstein RD. Tumor antigen presentation by murine epidermal cells. J Immunol 1991;146:3656-61.
56. Halliday GM, MacCarrick GR, Muller HK. Tumour promoters but not initiators deplete Langerhans cells from murine epidermis. Br J Cancer 1987;56:328-30.
57. Strauss GH, Bridges BA, Greaves M, Hall-Smith P, Price M, Vella-Briffa D. Inhibition of delayed hypersensitivity reaction in skin (DNCB test) by 8-methoxypsoralen photochemotherapy. Possible basis for pseudo-promoting action in skin carcinogenesis? Lancet 1980;2:556-9.
58. Alcaraz MV, Pathak MA, Rius F, Kollias N, Gonzalez S. An extract of Polypodium leucotomos appears to minimize certain photo-aging changes in a hairless albino mouse animal model: a pilot study. Photodermatol Photoimmunol Photomed 1999;15: 120-6.
59. Gilchrest BA, Eller MS. DNA photodamage stimulates melano-genesis and other photoprotective responses. J Investig Dermatol Symp Proc 1999;4:35-40.
60. Wang XT, McCullough KD, Wang XJ, Carpenter G, Holbrook NJ. Oxidative stress-induced phospholipase C-gamma 1 activation enhances cell survival. J Biol Chem 2001;276:28364-71.
61. De las Heras ME, Ledo E, Gonzalez S, Rocamora A, Ledo A. An extract of P. leucotomos (Difur) as an adjuvant in PUVA therapy. Med Cutan Iber 1997;25:103-7.